These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://sabrinaacpg945147.techionblog.com/39324154/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide